117
Views
5
CrossRef citations to date
0
Altmetric
Review

Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder

Pages 573-586 | Published online: 24 Feb 2005

Bibliography

  • SCAHILL L, SCHWAB-STONE M: Epidemiology of ADHD in school-age children. Child Adolesc. Psychiatr. Clin. N. Am. (2000) 9:541–555.
  • WEISS G, HECHTMAN L, MILROY T et al: Psychiatric status of hyperactives as adults: a controlled prospec-tive 15-year follow-up of 63 hyperactive children. J Am. Acad. Child Adolesc. Psychiatry (1985) 24:211–220.
  • •A hallmark study that confirmed the persistence of ADHD symptoms into adulthood.
  • CONNERS CK, JETT JL: Attention Deficit Hyperactivity Disorder (in adults and children). Compact Clinicals, Kansas City, Missouri, USA (1999).
  • BIEDERMAN J: Attention-deficit/hyperactivitydisorder: a life-span perspective. J Clin. Psychiatry (1998) 59 (Suppl. 7):4–16.
  • BIEDERMAN J, FARAONE S, MILBERGER S et al.: Predic-tors of p ersistence and remission of ADHD into adoles-cence: results from a four-year prospective follow-up study. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:343–351.
  • SPENCER T, BIEDERMAN J, WILENS TE et al: Adults withattention-deficit/hyperactivity disorder: a controver-sial diagnosis. J. Clin. Psychiatry (1998) 59 (Suppl. 7):59–68.
  • SILVER LB: Attention-deficit/hyperactivity disorder inadult life. Child Adolesc. Psychiatr. Clin. N Am. (2000) 9:511–523.
  • CASTELLANOS FX, GIEDD JN, MARCH WL et al.: Quantita-tive brain magnetic resonance imaging in attention-deficit hyperactivity disorder. Arch. Gen. Psychiatry (1996) 53:607–616.
  • SWANSON J, CATELLANOS FX, MURIAS M etal.: Cognitiveneuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Curt-. Opin. Neurobiol (1998) 8:263–271.
  • FILIPEK PA: Neuroimaging in the developmentaldisorders: the state of the science. J Child Psycho]. Psychiatr. (1999) 40:113–128.
  • ELIA J, AMBROSINI PJ, RAPOPORT JL: Treatment ofattention-deficit/hyperactivity disorder. N Eng]. J. Med. (1999) 340:780–788.
  • THAPAR A, HOLMES J, POULTON K et al.: Genetic basis ofattention deficit and hyperactivity. Br. J Psychiatry (1999) 174:105–111.
  • JENSEN PS: ADHD: current concepts on etiology, pathophysiology and neurobiology. Child Adoles. Psychiatr. Clin. N Am. (2000) 9:557–572.
  • SMALLEY SL, MCGOUGH JJ, DEL'HOMME Metal.: Familial clustering of symptoms and disruptive behaviors in multiplex families with attention-deficit/hyperac-tivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39:1135–1143.
  • COOK EH, STEIN MA, KRASOWSKI MD et al.: Association of attention deficit disorder and the dopamine transporter gene. Am]. Hum. Genet. (1995) 56:993–998.
  • GILL M, DALY G, HERON S, HAWI Z, FITZGERALD M: Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol. Psychiatry (1997) 2:311–313.
  • LAHOSTE GJ, SWANSON JM, WIGAL SB et al.: Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry (1996) 1:121–124.
  • FARAONE SV, BIEDERMAN J, WEIFFENBACH B et al.: Dopamine at gene 7-repeat allele and attention deficit hyperactivity disorder. Am. J. Psychiatry (1999) 156:768–770.
  • MURPHY P, SCHACHAR R: Use of self-ratings in theassessment of symptoms of attention deficit hyperac-tivity disorder in adults. Am. J. Psychiatry (2000) 157:1156–1159.
  • ZAMETKIN AJ, ERNST M: Problems in the managementof attention-deficit-hyperactivity disorder. N Engl. J Med. (1999) 340:40–46.
  • CONNERS CK: Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J. Clin. Psychiatry (1998) 59 (Suppl. 7):24–30.
  • WARD MF, WENDER PH, REIMHERR FW: The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit disorder. Am. J. Psychiatry (1993) 150:885–890.
  • BROWN T: Brown Attention Deficit Disorder Scales: Manual. Psychological Corporation, San Antonio, Texas, USA (1996).
  • DUPAUL G: The ADHD Rating Scale: Normative Data, Reliability and Validity. University of Massachusetts Medical School, Worcester, Massachusetts, USA (1990).
  • CONNERS CK: Conners Adult Attention-Deficit Rating Scale. Multi-Health Systems, North Tonawanda, New York, USA (1998).
  • WALDMAN ID, ROWE DC, ABRAMOWITZ A et al.: Associa-tion and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am. J. Hum. Genet. (1998) 63:1767–1776.
  • SWANSON JM, FLODMAN P, KENNEDY J et al.: Dopamine genes and AMID. Neurosci. Biobehav. Rev. (2000) 24:21–25.
  • •An excellent summary of the genetic studies involving dopamine and its relationship to ADHD.
  • DOUGHERTY DD, BONAB AA, SPENCER TJ, RAUCH SL,MADRAS BK, FISCHMAN AJ: Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet (1999) 354(9196):2132–2133.
  • MTA CO-OPERATIVE GROUP: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (1999) 56:1073–1086.
  • ••Of great historical importance, this large, well-crafted studyconfirmed the primacy of stimulant medication for ADHD, at least in younger individuals.
  • STUBBE DE: Attention-deficit/hyperactivity disorderoverview. Child Adolesc. Psychiatr. Clin. N Am. (2000) 9:469–479.
  • MTA CO-OPERATIVE GROUP: Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (1999) 56 :1088–1096.
  • WILENS TE, SPENCER TJ: The stimulants revisited. ChildAdolesc. Psychiatr. Clin. N Am. (2000) 9:573–603.
  • •A good overall review of the pharmacokinetic, pharmacody-namic and practical clinical aspects of the stimulants.
  • SPENCER T, BIEDERMAN J, WILENS T et al: Pharmaco- therapy of attention-deficit hyperactivity disorder across the life cycle./ Am. Acad. Child Adolesc. Psychiatry (1996) 35:409–432.
  • •A dated but important summary of the phenomenology of adult ADHD and the evidence-based support for various pharmacotherapeutic approaches to this disorder.
  • CLURE C, BRADY KT, SALADIN ME, JOHNSON D, WAID R,RITTENBURY M: Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice. Am. J. Drug Alcohol Abuse (1999) 25:441–448.
  • DOWNEY KK, STELSON FW, POMERLEAU OF, GIORDANIB: Adult attention deficit hyperactivity disorder: psychological test profiles in a clinical population. J Nerv. Ment. Dis. (1997) 185:32–38.
  • BRAMBLE D: Psychostimulants and psychiatrists: theTrent Adult Psychiatry Psychostimulant Survey. J. Psychopharmacol. (2000) 14:67–69.
  • POPPER CW: Pharmacologic alternatives topsychostimulants for the treatment of attention-deficit/hyperactivity disorder. Child Adolesc. Psychiatr. Clin. N. Am. (2000) 9:605–646.
  • ARNOLD LE: Methylphenidate vs. amphetamine:comparative review. J Attention Disord. (2000)3:200–211.
  • PLISZKA SR, GREENHILL LL, CRISMON ML et al: The Tex asChildren's Medication Algorithm Project: report of the Texas Consensus Conference Panel on medication treatment of childhood attention-deficit/hyperactivity disorder. Part II: tactics. Attention-deficit/hyperac-tivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39:920–927.
  • SWANSON J, GUPTA S, GUINTA D et al: Acute toleranceto methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin. Pharmacol. Ther. (1999) 66:295–305.
  • •An intriguing study that prompted a revaluation of the optimal dose-response strategies for the most effective prescribing of stimulants, such as methylphenidate.
  • SWANSON J, GREENHILL L, WIGAL S et al.: Pharmacoki-netic and pharmacodynamic properties of ampheta-mine in ADHD children. Scientific proceedings of the 46th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Chicago, Illinois, USA (1999). Abstract NR–177.
  • WILENS TE: long-term efficacy and safety of Concerta(OROS methylphenidate HCL) extended release Tablets. Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry New York City, USA (2000). Abstract 64C.
  • GREENHILL LL, HALPERIN JM, ABIKOFF H: Stimulantmedications. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:503–512.
  • WILENS TE, BIEDERMAN J, SPENCER TJ et al: Controlledtrial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder./ Clin. Psycho-pharmacol (1999) 19:257–264.
  • CASTANEDA R, LEVY R, HARDY M, TRUJILLO M: long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults. Psychiatr. Serv. (2000) 51:169–171.
  • MARGOLIN A, AVANTS SK, KOSTEN TR: Pemoline for thetreatment of cocaine dependence in methadone maintained patients. J. Psychoactive Drugs (1996) 28:301–304.
  • HORRIGAN JP, BARNHILL LJ: low-dose amphetaminesalts and adult attention-deficit/hyperactivity disorder. J. Clin. Psychiatry (2000) 61:414–417.
  • SPENCER T, WILENS T, BIEDERMAN J, KAGAN J,BEARMAN S: Pharmacodynamics of Adder all in adults with attention-deficit/hyperactivity disorder. Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract P32.
  • MCGOUGH JJ, GREENHILL L, BIEDERMAN J et al.: PK/PDanalyses of 5LI381 in pediatric ADHD. Abstract P40, scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000).
  • PATRICK KS, STRAUGHN AB, JARVI EJ, BREESE GR,MEYER MC: The absorption of sustained-release methylphenidate formulation compared to an immediate-release formulation. Biopharm. Drug Dispos. (1989) 10:165–171.
  • PELHAM WE, GREENSLADE KE, VODDE-HAMILTON M etal.: Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine and pemoline. Pediatrics (1990) 86:226–237.
  • PATERSON R, DOUGLAS C, HALLMAYER J, HAGAN M, KRUPENIA Z: A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust. NZ. J Psychiatry (1999) 33:494–502.
  • TAYLOR FB, RUSSO J: Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc. Psychopharmacol. (2000) 10:311–320.
  • GREENHILL LL, ELLIOTT GR, SWANSON JM, WILENS TE, JENSEN P: Development of new long-duration stimulant for ADHD:Alza's Concerta. Scientific proceed-ings of the 47th Annual Meeting of theAmerican Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract S64.
  • MODI NB, LINDEMULDER B, GUPTA SK: Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HC1) formulation. J. Clin. Pharmacol (2000) 40:379–388.
  • SWANSON JM: Development and clinical trial testing of Concerta for the treatment of ADHD in children. Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract 64B.
  • GREENHILL LL: Once-daily, methylphenidate modified-release (MPH MR) treatment of attention-deficit/hyperactivity disorder (ADHD). Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract P34.
  • QUINN D: Methylphenidate: the role of the d-isomer. In: Ritalin: Theory and Practice. Greenhill L, Osman B (Eds.), Mary Ann Liebert, New York, USA (1999):369–374.
  • WILENS TE, BIEDERMAN J, PRINCE J et al.: Six-week,double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am. J. Psychiatry (1996) 153:1147–1153.
  • LEONARD HL, MEYER MC, SWEDO SC et al.: Electrocar-diographic changes during desipramine and clomipramine treatment in children and adolescents. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34:1460–1468.
  • POPPER CW, ZIMNITZKY B: Sudden death putatively related to desipramine treatment in youth: a fifth case and a review of speculative mechanisms. J Child Adolesc. Psychopharmacol (1995) 5:283–300.
  • WENDER PH, REIMHERR FW: Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am. J. Psychiatry (1990) 147:1018–1020.
  • GOLDSTEIN MG: Bupropion sustained release and smoking cessation. J Clin. Psychiatry (1998) 59 (Suppl. 4):66–72.
  • DUNNER DL, ZISOOK S, BILLOW AA, BATEY SR, JOHNSTON JA, ASCHER JA: A prosp ective safety surveil-lance study for bupropion sustained release in the treatment of depression. J. Clin. Psychiatry (1998) 59:366–373.
  • WILENS T, SPENCER T, BIEDERMAN J et al.: A controlledtrial of bupropion SR for attention deficit hyperac-tivity disorder in adults. Scientific proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit Program of the NIMH. Boca Raton, Florida, USA (1999). Poster Abstract 29.
  • SWANSON J, SALEM, WEBSTER C, LAURENZA A, ASGHAR-NEJAD M: Pediatric pharmacokinetics/pharmacody- n am icsofGW32 065 9inattention-deficit/hyperactivity disorder (ADHD). Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract P28.
  • DEVEAUGH-GEISS J, CONNERS CK, SARKIS E et al.: Efficacy of GW320659 in children with attention-deficit/hyperactivity disorder. Abstract P29, scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000).
  • LEAKE CD: The Amphetamines. Charles C. Thomas, Spring-field, Illinois, USA (1958):3–18.
  • ••A detailed summary dating back more than four decadesthat offers valuable scientific and clinical data that is only now being rediscovered by investigators of drug therapies for ADHD.
  • GOLDEN RN, NICHOLAS L: Antidepressant efficacy ofvenlafaxine. Depress. Anxiety (2000) 12 (Suppl. 0:45–49.
  • ROSEBOOM PH, KALIN NH: Neuropharmacology of venlafaxine. Depress. Anxiety (2000) 1 2 (Suppl. 0:20–29.
  • HEDGES D, REIMHERR FW, ROGERS A, STRONG R, WENDER PH: An open trial of venlafaxine in adults patients with attention deficit hyperactivity disorder. Psychopharmacol. Bull. (1995) 31 :779–783.
  • ADLER LA, RESNICK S, KUNZ M, DEVINSKY O: Open-label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol. Bull. (1995) 31 :785–788.
  • FINDLING RL, SCHWARTZ MA, FLANNERY DJ, MANOS MJ: Venlafaxine in adults with attention-deficit/hyperac-tivity disorder: an open clinical trial. J. Clin. Psychiatry (1996) 57:184–189.
  • DALLAL A, CHOUINARD G: Withdrawal and reboundsymptoms associated with abrupt discontinuation of venlafaxine.j Clin. Psychopharmacol. (1998) 18:343–344.
  • MACKAY FR, DUNN NR, MARTIN RM eta].: Newer antide-pressants: a comparison of tolerability in general practice. Br. J. Gen. Pract (1999) 49:892–896.
  • HEILIGENSTEIN JH, SPENCER TJ, FARIES DE, BIEDERMAN J, KRATOCHVIL C, CONNERS CK: Efficacy of tomoxetine vs. placebo in pediatric outpatients with ADHD. Scientific proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. New York City, USA (2000). Abstract P11.
  • SPENCER T, BIEDERMAN J, WILENS T et al.: Effectivenessand tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J Psychiatry (1998) 155:693–695.
  • REIDERER P, REYNOLDS GP: Deprenyl is a selective inhibitor of brain MAO-Bin the long-term treatment of Parkinson's disease. Br. J Clin. Pharmacol. (1980) 9:98–99.
  • SZOKO E, KALASZ H, MAGYAR K: Biotransformation of deprenyl enantiomers. Eur. J. Drug Metab. Pharma-cokinet (1999) 24:315–319.
  • ERNST M, LIEBENAUER LL, TEBEKA D et al.: Selegiline in ADHD adults: plasma monoamines and monoamine metabolites. Neuropsychopharmacol. (1997) 16:276–284.
  • HEINONEN EH, MYLLYLA V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Sal (1998) 19:11–22.
  • DALLO J, YEN TT, KNOLL J: The aphrodisiac effect of (-)deprenyl in male rats. Acta Physiol. Hung. (1990) 75 (Suppl.):75–76.
  • MAHMOOD I: Clinical pharmacokinetics and pharma-codynamics of selegiline: an update. Clin. Pharma-cokinet. (1997) 33:91–102.
  • ROHATAGI S, BARRETT JS, DEWITT KE, MORALES RJ: Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm. Drug Dispos. (1997) 18:567–584.
  • PRENDERGAST MA, JACKSON WJ, TERRY AV, DECKER MW, ARNERIC SP, BUCCAFUSCO JJ: Central nicotinic receptor agonists ABT-418, ABT-089 and (-)-nicotine reduce distractibility in adult monkeys. Psychopharma-cology (Bed.) (1998) 1 3 6:50–58.
  • WILENS TE, BIEDERMAN J, SPENCER TJ et al.: A pilotcontrolled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am. J Psychiatry (1999) 156:1931–1937.
  • SUGIMOTO H, YAMANISHI Y, IIMURA Y, KAWAKAMI Y:Donepezil hydrochloride (E2020) and other acetyl-cholinesterase inhibitors. CUIT. Med. Chem. (2000) 7:303–339.
  • GREENBERG SM: Donepezil in the treatment of Alzheimer's disease. Arch. Neurol. (2000) 57:1380.
  • KISHNANI PS, SPIRIDIGLIOZZI GA, HELLER JH et al.: Donepezil for Down's syndrome. Am. J Psychiatry (2001) 1 5 8: 143.
  • WHELAN FJ, WALKER MS, SCHULTZ SK: Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. Ann. Clin. Psychiatry (2000) 12:131–135.
  • HOOPES SP: Donepezil for Tourette's disorder and ADM. J. Clin. Psychopharmacol (1999) 1 9:381–382.
  • WILENS TE, BIEDERMAN J, WONG J, SPENCER TJ, PRINCE JB: Adjunctive donepezil in attention deficit hyperac-tivity disorder in youth: case series. J Child Adolesc. Psychopharmacol. (2000) 10:217–222.
  • BROUGHTON RJ, FLEMING JA, GEORGE CF et al.: Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology (1997) 49:444–451.
  • SCATES AC, DORAISWAMY PM: Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. Ann. Pharmacother. (2000) 34:1302–1312.
  • GARATTINI S: Pharmacology of amineptine, an antide-pressant agent acting on the dopaminergic system: a review. Int. Clin. Psychopharmacol. (1997) 1 2 (Suppl. 3):515–519.
  • MONTEJO AL, LLORCA G, IZQUIERDO JA et al.: Sexual dysfunction with antidepressant agents: effect of the change to amineptine in patients with sexual dysfunc-tion secondary to SSRIs. Actas. Esp. Psiquiatr. (1999) 27:23–34.
  • GIOVANNINI MG, BARTOLINI L, BACCIOTTINI L, GRECO L, BLANDINA P: Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia. Behav. Brain Res. (1999) 104:147–155.
  • WILENS TE, BIEDERMAN J, SPENCER TJ, PRINCE J: Pharmacotherapy of adult attention deficit/hyperac-tivity disorder: a review. J. Clin. Psychopharmacol (1995) 15:270–279.
  • http://www.boston1ifesciences.com/news41.htm
  • http://www.shiregroup/com/4_rd/401_rd_cns03.html
  • http://www.celltechgroup.com/company_information/pre ss_releases/celltech_grou.../021100.htm
  • http://www.noven.com/PR030200.htm
  • h ttp : //www .biosp ace . co m/news_story .cfm?StoryId = 1108604
  • http://www.findarticles.com/m0FQN/2000_Feb_28/596139 10/pl/article.jhtml
  • http://www.biospace.com/ct/detail.cfm?ClinicalID = 182304
  • http://www.pslgroup.com/dg/1db532.htm
  • http://www.gliatech.com/pages/drug-development/index. html
  • http://www.centerwatch.com/patient/studies/stu 1920521.ht ml
  • http://www.cortexpharm.com/html/news/04-19-00.html
  • http://www.shiregroup.com/4_rd/401_rd_cns04.html

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.